Michael Verneris, MD

Philosophy of Care:

To provide superior care through a combination of compassion and creative, cutting-edge approaches.

Medical Title:

Academic Appointments:

Clinical Interests:

Languages Spoken:


Board Certifications:

2003, Alexander Charles Jundt Research Award, University of Minnesota

2000, Honorable Mention, Young Investigator Award, American Society of Pediatric Hematology/Oncology

1999, American Society of Hematology Travel Award, New Orleans, Louisiana

1995, AACR Workshop Attendance Scholarship titled Molecular Biology in Clinical Oncology, Aspen, CO

1992, Graduated Medical School With Honors (awarded to upper 10%, AOA not offered)

1993, Golden Butterfly Award,Children's National Medical Center

Verneris MR, Burke MJ. Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep. 2010 Jul;5(3):157-62.

Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia (ALL) following reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009 Mar 26;113(13):2902-5. PMC Journal – In Process.

Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant. 2009 Jan;43(2):107-13.

MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR, Blazar BR, Wagner JE. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood. 2009 Mar 12;113(11):2410-5. PMCID: PMC2656268.

Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clinical Oncology. 2009 Aug 1;27(22)3634-41. PMCID: PMC2720079.

Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Aug;44(3):169-74.

Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE. Relapse risk after umbilical cord blood transplantation: enhanced graft versus leukemia effect in recipients of two units. Blood. 2009 Nov 5;114(19):4293-9. PMCID: PMC2774557.

Tang Q, Grzywacz B, Wang H, Kataria N, Cao Q, Wagner JE, Blazar BR, Miller JS, Verneris MR. Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J Immunol. 2008 Oct 1;181(7):4507-15. PMCID: PMC2614673.

Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, Lee AB, Blazar BR, Cornfield DN, Miller JS, Verneris MR. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood. 2007 Sep 1;110:1530-1539. PMCID: PMC1975839.

Miller JS, Cooley S, Parham P, Farag SS, Verneris M, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007 Jun 1;109:5058-61. PMCID: PMC1885526.


Discrimination is Against the Law. We comply with applicable Federal civil rights laws. We do not discriminate against, exclude or treat people differently because of race, color, national origin, age, disability or sex.
 Visit Other Fairview Sites 
(c) 2017 Fairview Health Services. All rights reserved.